Targeting cancer

Gerard Cagney gerard.cagney at utoronto.ca
Sun Oct 1 22:25:02 EST 2000


good idea. look at some recent mRNA expression studies using tumor tissue and
see if you are right

Emir Khatipov wrote:

> Hello,
> Could someone summarize (or just give a short introduction into) current
> status of targeting cancer therapeutics: are there any preferable tissue or,
> most important, cancer specific targets that are being investigated now or
> which ones have been studied and became classical and are routinely used in
> practice. By targets I mostly mean proteins that are getting higher
> expressed in cancer cells than in the normal tissue, so that therapeutics
> could be delivered and selectively accumulated in cancer cells rather than
> in normal ones. My particular interest is whether there is any relevance
> available so far on using metabolic enzymes as potettial specific targets
> for untitumor treatment.
>
> I just was thinking that if a cancer tissue is growing faster than normal
> tissue, it could be quite limited in nutrients like nitrogen, sulphur, etc.,
> as well as oxygen (unless angeogenesis would not provide enough compensation
> for the nutrient limitation).
> Nutrient deprivation would trigger expression of enzymes or forms of enzymes
> that have higher affinity for growth substrates, and those enzymes may
> function as nice targets. Does it make sense?
>
> Another relevant question is whether there is a noticeable difference in
> metabolizm (carbon, nitrogen, phosphorus, etc.) in prostate cancer cells vs.
> normal prostate cells.
>
> Any guides and references would be highly appreciated.
>
> Thanks.
> Emir

--
Gerard Cagney
Program in Proteomics and Bioinformatics, Banting and Best Institute of Medical
Research, Room 416, 112 College Street, Toronto, Ontario, M5G 1L6, CANADA
Tel. (416) 946 7282 Fax (416) 978 8528 email: gerard.cagney at utronto.ca
http://www.utoronto.ca/emililab/







More information about the Methods mailing list